Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-EC-amifostine
- Development stage
- Preclinical
- Lead developer
- CellPoint
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
**177Lu-EC-amifostine** is an investigational **radiopharmaceutical** developed by **CellPoint** as part of a theranostic platform built around EC-amifostine. It consists of the beta-emitting radionuclide **lutetium-177** linked to **EC-amifostine**, an ethylenedicysteine conjugate of amifostine designed to localize where **alkaline phosphatase** activity is elevated. According to company disclosures, EC-amifostine is metabolized by alkaline phosphatase to a thiol analog that can scavenge free radicals and stabilize DNA, while the lutetium-177 payload provides localized beta radiation. The program was publicly described in 2020 as a potential therapy to assess, treat, and follow patients with **COVID-19**, particularly at sites of inflammation or infection, but publicly available evidence indicates very early development with no clear clinical-stage progression.
- Other names
- lutetium-177 EC-amifostinelutetium177 EC-amifostinelutetium 177 EC-amifostine
02
Targets
ALPL (Tissue-nonspecific alkaline phosphatase)
Beyond the preview
Go deeper on 177Lu-EC-amifostine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-EC-amifostine.